Our results indicate that Ikaros directly suppresses BCL6 but promotes BACH2 expression in B-ALL patients, and that patients with BCL6highBACH2low expression also have dysfunctional Ikaros and represent a subset of high-risk B-ALL. Here, BACH2 is linked to precursor B-cell acute lymphoblastic leukemia.